Navigation Links
InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
Date:10/3/2009

Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of their diagnostic ad preclinical grade material very fast and in highest quality, including authentic human glycosylation patterns, using the novel and proprietary CAP-TTM transient expression system.

CAP-TTM Technology is based on CAP cells, the stable cell line from CEVEC. The non-tumor origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.

After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, e.g. HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line, Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals GmbH states.

Rainer Lichtenberger, CEO of CEVEC, adds. Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs goal becoming the leading cell line supplier for protein production with human cell expression systems.


About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne, Germany. Based on their experience and theirlongstanding collaborative work they had experienced a lack of innovative expression systems formore efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVECs novel proprietary human CAP and CAP-T expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.


About InVivo BioTech Services GmbH - www.invivo.de
InVivo is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over ten years experience in mammalian cell culture and protein production. More than 1100 different hybridomas have been cultivated in InVivos proprietary serum-free media ISF1 for high productivity and cost benefits in cultivation and purification. Furthermore InVivo offers the complete range of modern protein expression techniques. Starting from synthetic or amplified cDNA your protein can be stable expressed in bacteria, insect and mammalian cell lines or alternatively transient expressed.



Contact:
Wolfgang Kintzel
Chief Commercial Officer / Geschftsfhrer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Strae 62
D-51105 Kln
Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com
www.cevec-pharmaceuticals.com


'/>"/>
b3c newswire

Related biology news :

1. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
2. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
3. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
4. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
5. Bacteria from sponges make new pharmaceuticals
6. MSU licenses plant oil enhancement technology to BASF Plant Science
7. UGA licenses technology to make fuel from dead forests and agricultural waste
8. UGA licenses new Bermuda grass that thrives in sun and shade
9. WARF signs license agreement with Pfizer for human embryonic stem cells
10. FluChip technology licensed to combat deadly flu virus
11. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):
(Date:9/20/2017)... Dallas-Fort Worth, Texas (PRWEB) , ... September 20, 2017 , ... ... people, stem cell therapy succeeded after standard medicine failed. Many of these people had ... - Progress, Not Regression Free Download (pdf) , “Neil ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... a standard fume hood and a high-performance fume hood. Along with the advantages ... and applications for ductless vs. ducted hoods in the laboratory. , Attendees will ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample ...
(Date:9/19/2017)... Austin, TX (PRWEB) , ... ... ... New York State Department of Financial Services (NYS DFS) cybersecurity ... all regulated banking, finance and insurance organizations operating in the state (“Covered ...
Breaking Biology Technology: